The treatment results of patients with hepatocellular carcinoma

Introduction. Hepatocellular carcinoma (HCC) is a primary tumor, accounting for 80–85 % of all malignant liver tumors. According to world statistics, the incidence of HCC ranks 6th, and mortality – 3rd. The prevalence of the disease in the Russian Federation has increased by 8 % over the past 5 years and is 4–5 cases per 100 thousand population per year, while stages III–IV account for about 80 %. Treatment of this pathology is a complex task and should take into account many factors. The aim of the study was to analyze the treatment results of patients with HCC for the period from 2008 to 2024. Materials and methods of research. A retrospective analysis of the treatment of 197 patients with hepatocellular carcinoma (HCC) was performed, the average age was 61.3 ± 8.5 years, men – 140 (71 %), women – 57 (29 %). Liver resection was performed in 82 patients, locoregional techniques were performed in 119 patients. Treatment results. The average duration of the operation was 179 ± 28,3 min; the average bed-day was 11 ± 3 days; the survival rate was 83 % at one year, 75 % at two years, 50 % at three years, and 32 % at five years. The time of LRT procedures were as follows: RFA –12 ± 2,8 min, MVA – 7 ± 2,3 min, LA – 6 min. The survival rate after RFA of liver tumors was 81% at one year, 62 % at two years, 39 % at three years, and 28 % at five years. When performing MVA of liver tumors, the survival rate was 83 % at one year, 67 % at two years, 42 % at three years, and 31 % at five years. Conclusion. An integrated approach to the treatment of patients with primary liver cancer allows us to determine the optimal tactics, which increases the effectiveness of treatment, increases life expectancy and improves its quality, and makes it possible to use local methods in somatically burdened patients.